Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

03 avr. 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Announces Issuance of U.S. Patent Covering CLR 131 Use in Multiple Myeloma

MADISON, Wis., April 03, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
27 mars 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Granted Seminal U.S. Patent for Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles

MADISON, Wis., March 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
21 mars 2018 16h10 HE | Source: Cellectar Biosciences, Inc.

Cellectar Reports 2017 Financial Results and Provides a Corporate Update

MADISON, Wis., March 21, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
19 mars 2018 08h05 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences Granted Orphan Drug Designation for CLR 131 to Treat Neuroblastoma

MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
19 mars 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Host 2017 Financial Results and Business Update Conference Call on March 22, 2018

MADISON, Wis., March 19, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
15 mars 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Announces Late-Breaking Poster Presentations at AACR 2018 Featuring PDCs and CLR 131

MADISON, Wis., March 15, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
06 mars 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Phase 1 Clinical Data Demonstrating CLR 124 Uptake in Brain Tumors Accepted for Oral Presentation at the 12th World Congress of the World Federation of Nuclear Medicine and Biology

MADISON, Wis., March 06, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
05 mars 2018 08h00 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at Upcoming March Conferences

MADISON, Wis., March 05, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
08 févr. 2018 08h15 HE | Source: Cellectar Biosciences, Inc.

Cellectar Biosciences to Present at the 2018 BIO CEO & Investor Conference

MADISON, Wis., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
07 févr. 2018 08h15 HE | Source: Cellectar Biosciences, Inc.

Cellectar Receives USPTO Notice of Allowance for Patent Covering Use of CLR 131 in Multiple Myeloma

MADISON, Wis., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...

Page précédente

Page suivante